We will conduct an open label, non-comparative, observational study to evaluate the efficacy,
safety and tolerability of Olmesartan therapy in Taiwan patients with essential hypertension,
and the primary objective is the change in the 24-hour mean systolic blood pressure from
baseline to the day after post-treatment week-12 visit according to the ambulatory blood
pressure monitoring.